Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Upifitamab Rilsodotin in Combination with Carboplatin in Participants with High-Grade Serous Ovarian

An Open-Label, Multicenter, Dose Escalation and Expansion Study of Upifitamab Rilsodotin in Combination with Carboplatin in Participants with High-Grade Serous Ovarian Cancer: A Modular Study related to Upgrade Umbrella Master Study

Disease Types: Ovarian

Available at: Roanoke

An Open-Label, Multicenter, Dose Escalation and Expansion Study of Upifitamab Rilsodotin in Combination with Carboplatin in Participants with High-Grade Serous Ovarian Cancer: A Modular Study related to Upgrade Umbrella Master Study

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04907968?term=with+High-Grade+Serous+Ovarian+Cancer&draw=2&rank=9